AMPH - Amphastar Pharmaceuticals, Inc.
21.21
-1.710 -8.062%
Share volume: 684,104
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$22.92
-1.71
-0.07%
Fundamental analysis
56%
Profitability
61%
Dept financing
32%
Liquidity
75%
Performance
53%
Performance
5 Days
5.09%
1 Month
19.19%
3 Months
-12.59%
6 Months
-5.52%
1 Year
-2.47%
2 Year
-42.94%
Key data
Stock price
$21.21
DAY RANGE
$21.10 - $22.66
52 WEEK RANGE
$17.03 - $31.26
52 WEEK CHANGE
-$4.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
Company detail
CEO: Yong F. Zhang
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: amphastar.com
Employees: 1,620
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs.
Recent news